HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert L Sutherland Selected Research

Cyclins

2/2013Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.
2/2013Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.
7/2012Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
7/2011Cyclin D as a therapeutic target in cancer.
9/2009Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.
9/2009Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.
1/2009CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease.
7/2008Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.
1/2008Cell cycle machinery: links with genesis and treatment of breast cancer.
2/2006Cell cycle control in breast cancer cells.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert L Sutherland Research Topics

Disease

67Neoplasms (Cancer)
05/2015 - 06/2002
65Breast Neoplasms (Breast Cancer)
06/2020 - 01/2002
37Prostatic Neoplasms (Prostate Cancer)
12/2012 - 02/2002
17Carcinoma (Carcinomatosis)
06/2012 - 01/2002
9Pancreatic Neoplasms (Pancreatic Cancer)
05/2015 - 05/2005
9Carcinogenesis
01/2011 - 07/2003
8Neoplasm Metastasis (Metastasis)
07/2013 - 06/2007
7Ovarian Neoplasms (Ovarian Cancer)
01/2014 - 03/2003
7Disease Progression
07/2012 - 01/2004
6Lymphatic Metastasis
08/2009 - 04/2003
5Adenocarcinoma
03/2016 - 12/2002
5Margins of Excision
06/2012 - 04/2003
3Ovarian Epithelial Carcinoma
01/2014 - 07/2004
3Genomic Instability
02/2013 - 01/2012
3Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
09/2008 - 05/2004
3Squamous Cell Carcinoma of Head and Neck
10/2007 - 11/2004
3Extranodal Extension
08/2004 - 04/2003
2Inflammation (Inflammations)
08/2011 - 06/2006
2Ductal Carcinoma
06/2011 - 01/2002
2Hypoxia (Hypoxemia)
04/2011 - 02/2011
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2009 - 07/2008
2Alopecia (Baldness)
02/2007 - 04/2005
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/2005 - 09/2003
1Breast Cyst
06/2020
1Chromosome Aberrations (Chromosome Abnormalities)
02/2013

Drug/Important Bio-Agent (IBA)

32Proteins (Proteins, Gene)FDA Link
06/2020 - 08/2002
19Cyclin D1IBA
07/2011 - 01/2002
17Hormones (Hormone)IBA
01/2012 - 06/2002
15Estrogen ReceptorsIBA
11/2012 - 08/2002
14Messenger RNA (mRNA)IBA
07/2012 - 08/2002
13CyclinsIBA
02/2013 - 01/2002
11Estrogens (Estrogen)FDA Link
11/2013 - 06/2002
11Prostate-Specific Antigen (Semenogelase)IBA
10/2010 - 04/2003
10Estrogen Receptor Modulators (Antiestrogen)IBA
07/2012 - 06/2002
10Biomarkers (Surrogate Marker)IBA
05/2012 - 03/2003
9TamoxifenFDA LinkGeneric
11/2013 - 08/2003
8Androgen Receptors (Androgen Receptor)IBA
06/2020 - 01/2005
8DNA (Deoxyribonucleic Acid)IBA
05/2015 - 12/2007
7AndrogensIBA
06/2020 - 07/2003
7Phenobarbital (Luminal)FDA Link
11/2013 - 10/2009
7Cyclin EIBA
07/2012 - 11/2002
6Pharmaceutical PreparationsIBA
01/2014 - 09/2003
6ErbB Receptors (EGF Receptor)IBA
02/2013 - 11/2004
6SteroidsIBA
03/2010 - 08/2002
5ChromatinIBA
03/2016 - 08/2009
5LigandsIBA
09/2014 - 10/2007
5AntibodiesIBA
09/2014 - 10/2003
5Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2014 - 12/2003
5Tyrosine (L-Tyrosine)FDA Link
11/2013 - 08/2002
5Phosphotransferases (Kinase)IBA
01/2012 - 02/2006
5Progesterone Receptors (Progesterone Receptor)IBA
02/2011 - 09/2007
5Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2006 - 08/2002
4Fulvestrant (Faslodex)FDA Link
05/2011 - 08/2002
3Small Interfering RNA (siRNA)IBA
01/2014 - 05/2005
3CytokinesIBA
02/2013 - 03/2003
3persinIBA
12/2011 - 09/2006
3Phosphatidylinositols (Phosphatidylinositol)IBA
12/2010 - 07/2003
3beta CateninIBA
01/2010 - 01/2005
3Biological ProductsIBA
09/2009 - 09/2003
3Retinoblastoma ProteinIBA
01/2009 - 09/2003
3Epidermal Growth Factor (EGF)IBA
10/2007 - 08/2002
3Transforming Growth Factor beta (TGF-beta)IBA
06/2006 - 03/2003
3Cyclin-Dependent Kinase Inhibitor p16IBA
06/2005 - 12/2002
2Estrogen Receptor alphaIBA
01/2018 - 08/2009
2Interleukin-6 (Interleukin 6)IBA
09/2014 - 02/2013
2Monoclonal AntibodiesIBA
06/2011 - 08/2004
2Neuregulin-1 (Neuregulin 1)IBA
05/2011 - 08/2002
2Histones (Histone)IBA
01/2011 - 10/2010
2Tumor Biomarkers (Tumor Markers)IBA
01/2011 - 07/2004
2EnzymesIBA
10/2010 - 03/2009
2RNA (Ribonucleic Acid)IBA
07/2010 - 09/2003
2Protein Isoforms (Isoforms)IBA
09/2009 - 09/2007
2Selective Estrogen Receptor Modulators (SERM)IBA
01/2008 - 08/2003
2Progestins (Progestagens)IBA
01/2008 - 09/2007
2PhytochemicalsIBA
10/2007 - 09/2006
2Gefitinib (Iressa)FDA Link
10/2007 - 11/2004
2WD repeat containing planar cell polarity effectorIBA
07/2007 - 01/2004
2Oncogene Proteins (Oncogene Protein)IBA
12/2006 - 01/2002
2Tretinoin (Retinoic Acid)FDA LinkGeneric
08/2006 - 05/2005
2AntigensIBA
11/2005 - 10/2003
2OligonucleotidesIBA
05/2005 - 09/2003
2Growth Differentiation Factor 15IBA
03/2005 - 03/2003
2Immunoconjugates (Immunoconjugate)IBA
08/2004 - 10/2003
1Apolipoproteins D (Apo D)IBA
06/2020
1Histone Deacetylase InhibitorsIBA
05/2015
1MethyltransferasesIBA
05/2015
1VorinostatFDA Link
05/2015
1DeoxycytidineIBA
05/2015
1Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
09/2014
1Bromodeoxyuridine (BrdU)IBA
01/2014
1CDC2 Protein Kinase (Protein p34cdc2)IBA
01/2014
1Long Noncoding RNAIBA
01/2014
1CateninsIBA
07/2013
1Activating Transcription Factor 3IBA
07/2013
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
02/2013
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
02/2013

Therapy/Procedure

29Therapeutics
01/2014 - 07/2003
19Prostatectomy (Retropubic Prostatectomy)
12/2012 - 02/2002
4Drug Therapy (Chemotherapy)
02/2012 - 10/2009
1Brachytherapy
12/2012